Glenmark Pharmaceuticals announced that the company on 15 January 2021 redeeemed US $10,000,000 in aggregate principal amount of its 2021 Notes, representing approximately 5% of the aggregate principal amount of the 2021 Notes at the time of initial listing. As on the date of this announcement, no amount is outstanding in connection with the USD 200 million 4.5% Senior Notes due 2021 (2021 Notes).

Powered by Capital Market - Live News

Tadalafil tablets are generic version of Cialis tablets of Eli Lilly and Company. According to IQVIA, sales data for the 12 month period ending November 2020, the Cialis tablets achieved annual sales of approximately $125.5 million.

Glenmark also received tentative approval from United States Food & Drug Administration (USFDA) for Gabapentin Enacarbil extended-release tablets. The product is generic version of Horizant extended-release tablets of Arbor Pharmaceuticals, LLC. The Horizant market achieved annual sales of approximately $99.5 million.

Further, the drug maker received tentative approval for Apremilast tablets, a generic version of Otezla tablets of Amgen Inc. Otezla tablets achieved annual sales of approximately $2.7 billion.

Glenmark's current portfolio consists of 167 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the USFDA.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across generics, specialty and over-the-counter (OTC) business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology.

The drug maker's consolidated net profit slipped 8.4% to Rs 233.99 crore on 5.2% increase in net sales to Rs 2,908.12 crore in Q2 September 2020 over Q2 September 2019.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has received the United States Food & DrugAdministration's (USFDA) tentative approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg, the generic version of Otezla® Tablets, 10 mg, 20 mg and 30 mg, of Amgen, Inc.

The Otezla® Tablets, 10 mg, 20 mg and 30 mg market achieved annual sales of approximately $2.7 billion.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has received tentative approval by the U.S. FDA for Gabapentin Enacarbil Extended Release Tablets, 300 mg and 600 mg, the generic version of Horizant®1 Extended-Release Tablets, 300mg and 600 mg, of Arbor Pharmaceuticals, LLC.

The Horizant® market achieved annual sales of approximately $99.5 million.

Powered by Capital Market - Live News